Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617507 | 0.95 | — | — | |
| SCHEMBL3616250 | 0.71 | PDK1 (0.30) | — | |
| SCHEMBL467418 | 0.70 | CYP2A6 (0.42) | — | |
| SCHEMBL467651 | 0.66 | NPY5R (0.32) | — | |
| SCHEMBL20554077 | 0.64 | GAA (0.31) | GAA | |
| SCHEMBL118747 | 0.63 | DRD4 (0.45) | — | |
| SCHEMBL1638194 | 0.62 | ADRA2A (0.33) | — | |
| SCHEMBL1313301 | 0.62 | SIGMAR1 (0.39) | — | |
| SCHEMBL968063 | 0.60 | SIGMAR1 (0.43) | GAA | |
| SCHEMBL154828 | 0.60 | SIGMAR1 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2944637-B1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM CORP (JP) | 2020-02-19 | — | — | EP | disclosed |
| US-9783536-B2 | Nitrogen-containing heterocyclic compound or salt thereof | FUJIFILM CORPORATION (JP) | 2017-10-10 | — | — | US | disclosed |
| EP-2944637-A1 | NITROGEN-CONTAINING HETEROCYLIC COMPOUND OR SALT THEREOF | FUJIFILM Corporation (JP) | 2015-11-18 | — | — | EP | disclosed |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2015-11-12 | — | — | US | disclosed |
| WO-2015124606-A1 | N-SUBSTITUTED IMINO HETEROCYCLIC COMPOUNDS FOR COMBATING INVERTEBRATE PESTS | BASF SE (DE) | 2015-08-27 | — | — | WO | disclosed |
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-03 | — | — | US | disclosed |
| EP-2502909-A1 | AMINOPYRIDINE DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED | 2010-04-08 | — | — | US | disclosed |
| EP-2137195-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | Glaxo Group Limited (GB) | 2009-12-30 | — | — | EP | disclosed |
| WO-2008128953-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005710-A1 | AMINOPYRIDINE DERIVATIVE | DCX, NR0B1, NR4A1 | GAA 4837/4885 |
| US-20100087424-A1 | TRICYCLIC NITROGEN CONTAINING HETEROCYCLES AS ANTIBACTERIAL AGENTS | NRDC, NDC1, NANS | GAA 2952/4885 |
| US-20150322063-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND OR SALT THEREOF | NPM1, NAP1L1, REN | GAA 4057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.